Periodic zone-MPC with asymmetric costs for outpatient-ready safety of an artificial pancreas to treat type 1 diabetes.
A novel Model Predictive Control (MPC) law for an Artificial Pancreas (AP) to automatically deliver insulin to people with type 1 diabetes is proposed. The MPC law is an enhancement of the authors' zone-MPC approach that has successfully been trialled in-clinic, and targets the safe outpatient deployment of an AP. The MPC law controls blood-glucose levels to a diurnally time-dependent zone, and enforces diurnal, hard input constraints. The main algorithmic novelty is the use of asymmetric input costs in the MPC problem's objective function. This improves safety by facilitating the independent design of the controller's responses to hyperglycemia and hypoglycemia. The proposed controller performs predictive pump-suspension in the face of impending hypoglycemia, and subsequent predictive pump-resumption, based only on clinical needs and feedback. The proposed MPC strategy's benefits are demonstrated byin-silicostudies as well as highlights from a US Food and Drug Administration approved clinical trial in which 32 subjects each completed two 25 hour closed-loop sessions employing the proposed MPC law.
Harvard John A. Paulson School of Engineering & Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Ravi
R
Gondhalekar
Harvard John A. Paulson School of Engineering & Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Eyal
E
Dassau
Harvard John A. Paulson School of Engineering & Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Francis J
FJ
Doyle
Artificial pancreas; Model predictive control; Periodic control; Safety-critical control; Type 1 diabetes mellitus
Physiol Meas. 2004 Aug;25(4):905-20
15382830
Diabet Med. 2006 Jan;23(1):1-12
16409558
Diabetes. 2006 Dec;55(12):3344-50
17130478
J Process Control. 2008 Feb;18(2):149-162
19190726
Med Biol Eng Comput. 2009 Mar;47(3):343-52
19214613
J Diabetes Sci Technol. 2009 Jan;3(1):44-55
19444330
J Diabetes Sci Technol. 2008 Jul;2(4):630-5
19885239
J Diabetes Sci Technol. 2008 Sep;2(5):863-72
19885271
J Diabetes Sci Technol. 2009 May 01;3(3):536-44
20144293
IEEE Eng Med Biol Mag. 2010 Mar-Apr;29(2):53-62
20659841
J Diabetes Sci Technol. 2010 Jul 01;4(4):961-75
20663463
IEEE Rev Biomed Eng. 2009 Jan 1;2:54-96
20936056
J Diabetes Sci Technol. 2011 Mar 01;5(2):368-79
21527108
Diabetes. 2011 Nov;60(11):2672-82
22025773
J Diabetes Sci Technol. 2011 Sep 01;5(5):1283-6
22027329
IEEE Trans Biomed Eng. 2012 Jul;59(7):1839-49
22127988
Diabetes. 2012 Sep;61(9):2230-7
22688340
J Diabetes Sci Technol. 2012 Nov 01;6(6):1345-54
23294779
N Engl J Med. 2013 Feb 28;368(9):824-33
23445093
Diabetes Technol Ther. 2013 May;15(5):386-400
23544672
Diabetes Technol Ther. 2013 Aug;15(8):628-33
23829285
J Diabetes Sci Technol. 2013 Nov 01;7(6):1446-60
24351171
Diabetes Care. 2014;37(5):1191-7
24757226
Diabetes Care. 2014;37(5):1204-11
24757227
J Diabetes Sci Technol. 2014 Jan 1;8(1):26-34
24876534
Diabetes Care. 2014 Jul;37(7):1789-96
24929429
N Engl J Med. 2014 Jul 24;371(4):313-325
24931572
IEEE Trans Biomed Eng. 2014 Dec;61(12):2939-47
25020013
Diabetes Care. 2014 Nov;37(11):3025-32
25078901
J Clin Endocrinol Metab. 2015 Oct;100(10):3878-86
26204135
IEEE Trans Biomed Eng. 2016 Jun;63(6):1192-1200
26452196
Proc Am Control Conf. 2014 Jun;2014:4224-4230
28479660
Med Prog Technol. 1979 Jun 15;6(3):91-8
481365
N Engl J Med. 1993 Sep 30;329(14):977-86
8366922
Horm Metab Res. 1977;Suppl 7:23-33
873440
IEEE Trans Biomed Eng. 1999 Feb;46(2):148-57
9932336